Loading...
•
Jun 30, 2024
Agenus Q2 2024 Earnings Report
Agenus reported financial results for the second quarter of 2024 and provided a corporate update.
Key Takeaways
Agenus reported revenue of $23.5 million for the second quarter of 2024 and a net loss of $54.8 million. The company's cash balance was $93.7 million at the end of the quarter. Agenus is focused on advancing its BOT/BAL program and is in discussions with potential partners.
Agenus released interim data from its global randomized Phase 2 trial of BOT/BAL in relapsed/refractory MSS colorectal cancer.
Data from the BOT/BAL clinical program demonstrated activity across 10 different cancers and across early and late-stage disease.
Agenus initiated engagement with the European Medicines Agency (EMA) and will explore registration paths for BOT/BAL in other geographies.
Agenus closed the first tranche of its $75 million royalty financing led by Ligand Pharmaceuticals and is pursuing potential out-licensing transactions.
Forward Guidance
Agenus is focused on securing a global partnership for BOT/BAL and initiating a Phase 3 study in r/r MSS CRC.
Positive Outlook
- Agenus has gained alignment with the FDA on the proposed design and dosing regimen for its upcoming Phase 3 study in the r/r MSS CRC treatment setting.
- The company is in discussions with several major biopharma companies regarding a potential partnership for BOT/BAL.
- Agenus anticipates releasing further data later this year across the BOT/BAL program beyond MSS CRC.
- Agenus has received recent interest in partnerships for its wholly owned Chemistry, Manufacturing, and Controls (CMC) infrastructure.
- Agenus is launching a Named Patient Program for BOT/BAL to provide early access to eligible patients.
Challenges Ahead
- The FDA discouraged the submission of interim results for Accelerated Approval based on the dataset shared during the July End-of-Phase 2 meeting.
- Agenus plans to further engage the FDA with more mature data to support its AA strategy.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...